HALOZYME THERAPEUTICS, INC. (HALO)
Every FINRA and SEC series the site collects for HALOZYME THERAPEUTICS, INC.: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
14.6M
Short interest
settlement 2026-08-14
5.0
Days to cover
+4.4% vs prior
63.0%
Short share of volume
2026-09-11
14
Fails to deliver
settlement 2026-08-13
-$12.9M
Insider flow, 90 days
0 buys, 19 sells
As of 2026-09-11.
Short interest
FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSONAs of 14 August 2026, short interest in HALO is 14,636,927 shares, up 1,340,966 shares over the last month. Over the last 48 readings it ranged from 8,566,431 shares (29 November 2024) to 14,636,927 shares (14 August 2026). The latest reading sits at the top of that range. At the reported average volume of 2.9M shares a day that is 5.0 days to cover, elevated.
Embed this chartfree, with the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/halo" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-14 | 14,636,927 | +4.4% | 2,919,803 | 5.01 |
| 2026-07-31 | 14,022,134 | +5.5% | 1,679,119 | 8.35 |
| 2026-07-15 | 13,295,961 | +0.5% | 1,828,707 | 7.27 |
| 2026-06-30 | 13,226,223 | +2.1% | 2,108,787 | 6.27 |
| 2026-06-15 | 12,948,289 | -5.1% | 1,652,526 | 7.84 |
| 2026-05-29 | 13,644,245 | +1.9% | 1,680,327 | 8.12 |
| 2026-05-15 | 13,389,887 | -6.9% | 1,991,771 | 6.72 |
| 2026-04-30 | 14,381,741 | +0.9% | 1,407,549 | 10.22 |
| 2026-04-15 | 14,257,845 | +1.5% | 1,348,999 | 10.57 |
| 2026-03-31 | 14,046,350 | +2.5% | 1,493,288 | 9.41 |
| 2026-03-13 | 13,701,015 | +1.5% | 1,630,424 | 8.40 |
| 2026-02-27 | 13,498,344 | -2.1% | 2,199,321 | 6.14 |
| 2026-02-13 | 13,795,570 | +2.1% | 2,134,102 | 6.46 |
| 2026-01-30 | 13,515,827 | -0.6% | 1,490,869 | 9.07 |
| 2026-01-15 | 13,593,503 | -1.5% | 2,227,816 | 6.10 |
| 2025-12-31 | 13,800,472 | +10.4% | 1,395,958 | 9.89 |
| 2025-12-15 | 12,500,858 | +1.0% | 2,816,317 | 4.44 |
| 2025-11-28 | 12,372,896 | -0.8% | 2,042,714 | 6.06 |
| 2025-11-14 | 12,479,411 | +10.4% | 3,188,411 | 3.91 |
| 2025-10-31 | 11,305,141 | -1.8% | 1,477,599 | 7.65 |
| 2025-10-15 | 11,510,110 | +6.6% | 2,398,287 | 4.80 |
| 2025-09-30 | 10,797,290 | -8.3% | 2,208,182 | 4.89 |
| 2025-09-15 | 11,779,854 | -0.9% | 1,836,341 | 6.41 |
| 2025-08-29 | 11,883,269 | +12.4% | 2,069,526 | 5.74 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 11 September 2026, the short share of HALO volume is 63.0%, up 2.4 points over the last five sessions. Over the last 52 readings it ranged from 17.8% (14 August 2026) to 85.0% (17 July 2026). The latest reading is 12.4 points above the 30-session average of 50.7%, on 440K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-11 | 277K | 440K | 63.0% | 5,034 |
| 2026-09-10 | 173K | 455K | 38.1% | 9,977 |
| 2026-09-09 | 188K | 526K | 35.8% | 8,815 |
| 2026-09-08 | 319K | 744K | 42.9% | 23,578 |
| 2026-09-04 | 161K | 407K | 39.6% | 0 |
| 2026-09-03 | 541K | 892K | 60.7% | 56,364 |
| 2026-09-02 | 394K | 689K | 57.2% | 616 |
| 2026-09-01 | 215K | 412K | 52.0% | 1,259 |
| 2026-08-31 | 147K | 417K | 35.3% | 981 |
| 2026-08-28 | 207K | 578K | 35.7% | 928 |
| 2026-08-27 | 233K | 567K | 41.2% | 30,265 |
| 2026-08-26 | 166K | 510K | 32.5% | 6,671 |
| 2026-08-25 | 443K | 729K | 60.8% | 52,772 |
| 2026-08-24 | 299K | 660K | 45.3% | 398 |
| 2026-08-21 | 303K | 572K | 53.0% | 10,386 |
| 2026-08-20 | 215K | 444K | 48.4% | 466 |
| 2026-08-19 | 566K | 1.2M | 46.7% | 35,716 |
| 2026-08-18 | 403K | 889K | 45.4% | 8,058 |
| 2026-08-17 | 523K | 1.1M | 46.4% | 31,519 |
| 2026-08-14 | 158K | 889K | 17.8% | 858 |
| 2026-08-13 | 350K | 980K | 35.7% | 94,474 |
| 2026-08-12 | 1.3M | 2.0M | 67.3% | 184,264 |
| 2026-08-11 | 1.1M | 1.5M | 72.0% | 62,423 |
| 2026-08-10 | 1.1M | 1.8M | 58.4% | 218,715 |
| 2026-08-07 | 2.0M | 3.9M | 51.4% | 177,876 |
| 2026-08-06 | 495K | 1.0M | 48.7% | 23,820 |
| 2026-08-05 | 449K | 568K | 79.0% | 20,603 |
| 2026-08-04 | 397K | 554K | 71.6% | 24,229 |
| 2026-08-03 | 285K | 481K | 59.3% | 203 |
| 2026-07-31 | 467K | 592K | 78.9% | 456 |
Fails to deliver
SEC, by settlement date. JSONAs of 13 August 2026, the fails-to-deliver balance in HALO is 14 shares, down 857 shares over the last settlement date. Over the last 52 readings it ranged from 2 shares (5 February 2026) to 29,083 shares (5 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-13 | 14 | $101.79 | $1K |
| 2026-08-10 | 871 | $103.12 | $90K |
| 2026-08-07 | 4,876 | $85.76 | $418K |
| 2026-08-06 | 41 | $83.59 | $3K |
| 2026-08-05 | 108 | $83.23 | $9K |
| 2026-08-03 | 305 | $82.54 | $25K |
| 2026-07-31 | 1,515 | $83.30 | $126K |
| 2026-07-30 | 4,780 | $83.28 | $398K |
| 2026-07-23 | 50 | $77.82 | $4K |
| 2026-07-22 | 138 | $78.60 | $11K |
| 2026-07-21 | 18,373 | $77.09 | $1.4M |
| 2026-07-17 | 261 | $77.54 | $20K |
| 2026-07-15 | 17,716 | $75.05 | $1.3M |
| 2026-07-09 | 750 | $80.37 | $60K |
| 2026-07-06 | 4,643 | $79.45 | $369K |
| 2026-06-29 | 24,256 | $74.96 | $1.8M |
| 2026-06-26 | 8,279 | $72.64 | $601K |
| 2026-06-25 | 3,517 | $71.15 | $250K |
| 2026-06-24 | 3,233 | $69.62 | $225K |
| 2026-06-18 | 6 | $68.57 | $411 |
| 2026-06-15 | 129 | $69.50 | $9K |
| 2026-06-10 | 47 | $71.48 | $3K |
| 2026-06-05 | 29,083 | $71.60 | $2.1M |
| 2026-04-29 | 8,514 | $63.86 | $544K |
| 2026-04-28 | 950 | $64.49 | $61K |
| 2026-04-24 | 67 | $66.59 | $4K |
| 2026-04-23 | 215 | $68.40 | $15K |
| 2026-04-17 | 45 | $66.64 | $3K |
| 2026-04-16 | 36 | $68.05 | $2K |
| 2026-04-08 | 2,291 | $63.60 | $146K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at HALO reported 19 open-market sells worth $12.9M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Torley Helen (PRESIDENT AND CEO) on 2026-09-11.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-11 | Torley Helen | PRESIDENT AND CEO | Sell | 5K | $107.55 | $485K | 768K |
| 2026-09-11 | Torley Helen | PRESIDENT AND CEO | Sell | 15K | $107.15 | $1.7M | 772K |
| 2026-09-11 | Torley Helen | PRESIDENT AND CEO | Option exercise | 20K | $18.41 | $368K | 788K |
| 2026-09-10 | Torley Helen | PRESIDENT AND CEO | Sell | 5K | $107.58 | $582K | 768K |
| 2026-09-10 | Torley Helen | PRESIDENT AND CEO | Sell | 15K | $107.01 | $1.6M | 773K |
| 2026-09-10 | Torley Helen | PRESIDENT AND CEO | Option exercise | 20K | $18.41 | $368K | 788K |
| 2026-09-09 | Torley Helen | PRESIDENT AND CEO | Sell | 100 | $108.67 | $11K | 768K |
| 2026-09-09 | Torley Helen | PRESIDENT AND CEO | Sell | 7K | $107.82 | $711K | 768K |
| 2026-09-09 | Torley Helen | PRESIDENT AND CEO | Sell | 13K | $107.22 | $1.4M | 774K |
| 2026-09-09 | Torley Helen | PRESIDENT AND CEO | Option exercise | 20K | $18.41 | $368K | 788K |
| 2026-09-01 | Appelhans Dannielle | n/a | Grant | 1K | $0.00 | $0 | 1K |
| 2026-08-19 | Torley Helen | PRESIDENT AND CEO | Sell | 3K | $107.77 | $345K | 768K |
| 2026-08-19 | Torley Helen | PRESIDENT AND CEO | Sell | 10K | $107.22 | $1.0M | 771K |
| 2026-08-19 | Torley Helen | PRESIDENT AND CEO | Sell | 7K | $106.36 | $766K | 781K |
| 2026-08-19 | Torley Helen | PRESIDENT AND CEO | Option exercise | 20K | $18.41 | $368K | 788K |
| 2026-08-18 | Torley Helen | PRESIDENT AND CEO | Sell | 9K | $104.87 | $986K | 768K |
| 2026-08-18 | Torley Helen | PRESIDENT AND CEO | Sell | 5K | $104.11 | $510K | 777K |
| 2026-08-18 | Torley Helen | PRESIDENT AND CEO | Sell | 6K | $103.08 | $588K | 782K |
| 2026-08-18 | Torley Helen | PRESIDENT AND CEO | Option exercise | 20K | $18.41 | $368K | 788K |
| 2026-08-17 | Torley Helen | PRESIDENT AND CEO | Sell | 8K | $103.48 | $776K | 768K |
| 2026-08-17 | Torley Helen | PRESIDENT AND CEO | Sell | 9K | $102.55 | $923K | 775K |
| 2026-08-17 | Torley Helen | PRESIDENT AND CEO | Sell | 2K | $101.77 | $214K | 784K |
| 2026-08-17 | Torley Helen | PRESIDENT AND CEO | Sell | 500 | $100.46 | $50K | 786K |
| 2026-08-17 | Torley Helen | PRESIDENT AND CEO | Sell | 900 | $98.96 | $89K | 787K |
| 2026-08-17 | Torley Helen | PRESIDENT AND CEO | Option exercise | 20K | $18.41 | $368K | 788K |
| 2026-08-10 | Connaughton Bernadette | n/a | Sell | 2K | $102.80 | $167K | 40K |
| 2026-06-03 | Torley Helen | PRESIDENT AND CEO | Sell | 6K | $69.69 | $425K | 768K |
| 2026-06-03 | Torley Helen | PRESIDENT AND CEO | Sell | 2K | $68.74 | $137K | 774K |
| 2026-06-03 | Torley Helen | PRESIDENT AND CEO | Sell | 2K | $67.67 | $102K | 776K |
| 2026-06-03 | Torley Helen | PRESIDENT AND CEO | Sell | 400 | $66.37 | $27K | 777K |
| 2026-06-03 | Torley Helen | PRESIDENT AND CEO | Option exercise | 10K | $12.07 | $121K | 778K |
| 2026-06-02 | Torley Helen | PRESIDENT AND CEO | Sell | 3K | $66.75 | $227K | 768K |
| 2026-06-02 | Torley Helen | PRESIDENT AND CEO | Sell | 17K | $66.31 | $1.1M | 771K |
| 2026-06-02 | Torley Helen | PRESIDENT AND CEO | Option exercise | 20K | $12.07 | $241K | 788K |
| 2026-06-01 | Connaughton Bernadette | n/a | Sell | 2K | $66.21 | $108K | 44K |
| 2026-06-01 | Torley Helen | PRESIDENT AND CEO | Sell | 5K | $68.35 | $369K | 768K |
| 2026-06-01 | Torley Helen | PRESIDENT AND CEO | Sell | 13K | $67.41 | $876K | 773K |
| 2026-06-01 | Torley Helen | PRESIDENT AND CEO | Sell | 2K | $66.39 | $107K | 786K |
| 2026-06-01 | Torley Helen | PRESIDENT AND CEO | Option exercise | 20K | $12.07 | $241K | 788K |
| 2026-05-13 | Torley Helen | PRESIDENT AND CEO | Sell | 600 | $70.81 | $42K | 768K |
| 2026-05-13 | Torley Helen | PRESIDENT AND CEO | Sell | 4K | $69.79 | $276K | 768K |
| 2026-05-13 | Torley Helen | PRESIDENT AND CEO | Sell | 3K | $68.88 | $231K | 772K |
| 2026-05-13 | Torley Helen | PRESIDENT AND CEO | Sell | 2K | $68.10 | $143K | 776K |
| 2026-05-13 | Torley Helen | PRESIDENT AND CEO | Option exercise | 10K | $12.07 | $121K | 778K |
| 2026-05-12 | Torley Helen | PRESIDENT AND CEO | Sell | 3K | $73.12 | $205K | 768K |
| 2026-05-12 | Torley Helen | PRESIDENT AND CEO | Sell | 6K | $72.15 | $426K | 771K |
| 2026-05-12 | Torley Helen | PRESIDENT AND CEO | Sell | 10K | $71.37 | $700K | 776K |
| 2026-05-12 | Torley Helen | PRESIDENT AND CEO | Sell | 1K | $70.29 | $98K | 786K |
| 2026-05-12 | Torley Helen | PRESIDENT AND CEO | Sell | 100 | $67.85 | $7K | 788K |
| 2026-05-12 | Torley Helen | PRESIDENT AND CEO | Option exercise | 20K | $12.07 | $241K | 788K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
Planned sales (Form 144)
Newest first. JSON2 Form 144 notices on file for HALO worth $4.5M at the prices reported; 2 in the last 90 days worth $4.5M. Latest: CORTNEY A CAUDILL filed on 2026-08-11 to sell 41,702 shares ($4.3M) from 2026-08-11.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-11 | CORTNEY A CAUDILLOfficer | 42K | $4.3M | 0.037% | 2026-08-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-10 | BERNADETTE CONNAUGHTONDirector | 2K | $168K | 0.001% | 2026-08-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
13F holders
Tracked managers holding HALO at their latest 13F. JSON9 of the 30 tracked managers held HALO at their latest 13F, $601.3M in total at quarter-end prices. D. E. Shaw & Co. is the largest at $160.0M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 6 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| D. E. Shaw & Co. | 2026-06-30 | 2.0M | $160.0M | 0.08% | +145K |
| Two Sigma Investments | 2026-06-30 | 1.7M | $129.4M | 0.09% | +68K |
| Citadel Advisors | 2026-06-30 | 66.0M | $96.7M | 0.01% | +65.6M |
| AQR Capital Management | 2026-06-30 | 786K | $61.5M | 0.02% | -231K |
| Renaissance Technologies | 2026-06-30 | 480K | $37.5M | 0.05% | -252K |
| Bridgewater Associates | 2026-06-30 | 463K | $36.3M | 0.15% | -48K |
| Fisher Asset Management | 2026-06-30 | 428K | $33.5M | 0.01% | -17K |
| Citadel Advisors | 2026-06-30 | 422K | $33.1M | 0.00% | -19.0M |
| Citadel Advisors | 2026-06-30 | 11.9M | $13.3M | 0.00% | -54.1M |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 2026 (quarter ended 2026-06-30) HALOZYME THERAPEUTICS, INC. reported revenue of $481.0M, up 47.7% from the same quarter a year earlier, and net income of $229.9M (1.90 diluted EPS). In FY 2025 it generated $651.6M of operating cash flow and spent $342.4M on buybacks. As of 2026-06-30, cash was $163.1M against $1.94B of debt.
- Cash
- $163.1M
- Debt
- $1.94B
- Equity
- $143.5M
- Total assets
- $2.58B
- Shares outstanding
- 113,498,000
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $481.0M | $229.9M | 47.8% | 1.90 |
| Q1 2026 | 2026-03-31 | $376.7M | $150.0M | 39.8% | 1.22 |
| Q4 2025derived | 2025-12-31 | $451.8M | -$141.6M | -31.3% | n/a |
| Q3 2025 | 2025-09-30 | $354.3M | $175.2M | 49.5% | 1.43 |
| Q2 2025 | 2025-06-30 | $325.7M | $165.2M | 50.7% | 1.33 |
| Q1 2025 | 2025-03-31 | $264.9M | $118.1M | 44.6% | 0.93 |
| Q4 2024derived | 2024-12-31 | $298.0M | $137.0M | 46.0% | n/a |
| Q3 2024 | 2024-09-30 | $290.1M | $137.0M | 47.2% | 1.05 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $1.40B | $316.9M | $651.6M | $7.0M | $342.4M | n/a |
| FY 2024 | 2024-12-31 | $1.02B | $444.1M | $479.1M | $10.7M | $250.0M | n/a |
| FY 2023 | 2023-12-31 | $829.3M | $281.6M | $388.6M | $15.3M | $402.4M | n/a |
| FY 2022 | 2022-12-31 | $660.1M | $202.1M | $240.1M | $4.8M | $200.0M | n/a |
| FY 2021 | 2021-12-31 | $443.3M | $402.7M | $299.4M | $1.5M | $350.1M | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
HALOZYME THERAPEUTICS, INC. in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows HALOZYME THERAPEUTICS, INC. (HALO), SEC CIK 1159036, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-14.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-13.JSON and CSV
- Planned sales
- SEC EDGAR Form 144EDGAR read every 30 minutes; a notice is filed on or before the sell order. Latest 2026-08-11.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-09-11.JSON and CSV
- Company record
- EDGAR filing index for CIK 1159036Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 13 Sep 05:40 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
- KYMRKymera Therapeutics, Inc.
- ADPTAdaptive Biotechnologies Corp
- TWSTTwist Bioscience Corp
- KRYSKrystal Biotech, Inc.
- NBIXNEUROCRINE BIOSCIENCES INC
- RVMDRevolution Medicines, Inc.
- AMGNAMGEN INC
- MAZEMaze Therapeutics, Inc.
- GILDGILEAD SCIENCES, INC.
- RXRXRECURSION PHARMACEUTICALS, INC.
- APGEApogee Therapeutics, Inc.
- FENCFENNEC PHARMACEUTICALS INC.
- PCVXVaxcyte, Inc.
- BIIBBIOGEN INC.
- VORVor Biopharma Inc.
- EXELEXELIXIS, INC.
- SRRKScholar Rock Holding Corp
- ADMAADMA BIOLOGICS, INC.
- VCELVericel Corp
- TECHBIO-TECHNE Corp
- ARTVArtiva Biotherapeutics, Inc.
- BCRXBIOCRYST PHARMACEUTICALS INC
- VIRVir Biotechnology, Inc.
- IOVAIOVANCE BIOTHERAPEUTICS, INC.
Datasets
Frequently Asked Questions
How much of HALO is sold short?
What is HALO's daily short volume?
Does HALO have fails to deliver?
Are HALO insiders buying or selling?
Have HALO insiders filed to sell?
What did HALO report last quarter?
Which funds hold HALO?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.